CTNM

NASDAQ 已收盘

Contineum Therapeutics, Inc.

15.90 USD
+0.44-0.19%
2026-08-03
市值
$598.18M
市盈率
EPS
-1.72
股息率
52 周区间
5.71 – 16.91
成交量
430.20K
Beta
0.74
目标价
22.86
52W 低 5.7152W 高 16.91
价格走势

公司简介

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitt...